S100A12 Protein

A member of the S100 PROTEIN FAMILY that regulates INFLAMMATION and the immune response. It recruits LEUKOCYTES, promotes cytokine and chemokine production, and regulates leukocyte adhesion and migration. S100A12 can also function via binding to ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTORS, to stimulate innate immune cells.

Also Known As:

Networked: 421 relevant articles (14 outcomes, 78 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Foell, Dirk: 31 articles (01/2022 - 04/2003)
2.	Steiner, Jörg M: 19 articles (12/2019 - 12/2010)
3.	Heilmann, Romy M: 18 articles (01/2021 - 12/2010)
4.	Suchodolski, Jan S: 16 articles (01/2021 - 12/2010)
5.	Roth, Johannes: 15 articles (12/2015 - 04/2003)
6.	Day, Andrew S: 13 articles (01/2020 - 07/2006)
7.	Wittkowski, Helmut: 12 articles (11/2015 - 04/2004)
8.	Grützner, Niels: 10 articles (01/2021 - 12/2011)
9.	Geczy, Carolyn L: 10 articles (10/2017 - 01/2007)
10.	Leach, Steven T: 7 articles (01/2020 - 07/2006)

Related Diseases

1.	Crohn Disease (Crohn's Disease) 01/01/2023 - "The results obtained from this investigation suggest that measurements of pro-GN, PTX3 and S100A12 could prove beneficial in the diagnosis of Crohn's disease. " 04/01/2022 - "Fecal S100A12 is associated with future hospitalization and step-up of medical treatment in patients with Crohn's disease in clinical remission: a pilot study." 07/01/2006 - "Fecal S100A12: a novel noninvasive marker in children with Crohn's disease." 01/01/2022 - "This bioinformatic study elucidates S100A8, S100A9, S100A12 and CXCR2 as hub genes for the co-occurrence of Crohn's disease and peripheral artery disease. " 01/01/2022 - "Neutrophil Infiltration Characterized by Upregulation of S100A8, S100A9, S100A12 and CXCR2 Is Associated With the Co-Occurrence of Crohn's Disease and Peripheral Artery Disease."
2.	Inflammation (Inflammations) 06/05/2018 - "Differentially expressed gene (DEG) analysis suggested that genes related to psoriatic inflammation, including CXCL1, CXCL8 (IL-8), S100A8, S100A9, S100A12 and LCN2, were significantly downregulated in patients in remission from GPP. " 09/14/2015 - "Understanding the role of S100A12 and MPO in the pathogenesis of chronic intestinal inflammation in future may result in an improved understanding of canine chronic intestinal inflammation." 01/01/2022 - "The purpose of this study is to investigate the effect of S100A12 on inflammation and oxidative stress and to determine its clinical applicability in AMI. " 04/15/2014 - "Further, this study showed that fecal canine S100A12 is associated with the clinical disease activity, the severity of endoscopic lesions, and the severity of colonic inflammation in dogs with IBD. " 12/01/2013 - "This study demonstrated that the circulating sRAGE level was inversely associated with VCS in HD patients independent of the S100A12 level and the severity of systemic inflammation."
3.	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 11/01/2019 - "Questions Regarding the Relationship Between Serum S100A8/A9 and S100A12 Levels, and the Maintenance of Clinically Inactive Disease in Juvenile Idiopathic Arthritis: Comment on the Article by Hinze et al." 02/01/2010 - "Twenty patients with Juvenile Idiopathic Arthritis (JIA) and 10 healthy control subjects underwent measurement of S100A12 serum concentrations by sandwich ELISA. " 02/01/2010 - "Serum S100A12 and temporomandibular joint magnetic resonance imaging in juvenile idiopathic arthritis Egyptian patients: a case control study." 05/01/2005 - "Serum levels of S100A12 correlate with disease activity in juvenile idiopathic arthritis. " 04/01/2004 - "Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations."
4.	Atherosclerosis 06/01/2015 - "This study suggests that an elevated plasma S100A12 level was closely associated with atherosclerosis. " 09/01/2022 - "S100A12, and RAGE play a critical role in the development and progression of atherosclerosis. " 05/01/2022 - "Our observations suggest that S100A12 may be an emerging therapeutic target for atherosclerosis." 01/01/2014 - "S100A8, S100A9 and S100A12 are considered proinflammatory mediators of atherosclerosis. " 05/01/2013 - "The specific binding of quinoline-3-carboxamides to S100A12 attenuates S100A12-mediated features of accelerated murine atherosclerosis."
5.	Aortic Diseases 08/21/2012 - "By establishing a link between S100A12 expression and apoptosis of aortic smooth muscle cells, this study identifies novel S100A12 signaling pathways and indicates that S100A12 may be a useful molecular marker and possible target for treatment for human aortic diseases." 01/01/2017 - "Our findings suggested that reduction of S100A12 protects HVSMCs against H2O2-induced injury, and may be useful as a treatment for aortic disease." 01/01/2017 - "The aim of the present study was to investigate the protective effects of S100A12 reduction on hydrogen peroxide (H2O2)-induced human vascular smooth muscle cells (HVSMCs) injury and evaluate the relevance of S100A12 and aortic disease. " 12/01/2017 - "Increased levels of S100A12 and activated matrix metalloproteinase 2/9 (MMP-2/9) produced by human aortic smooth muscle cells (HASMCs) have recently implicated in the development of thoracic aortic disease. "

Related Drugs and Biologics

1.	Biomarkers (Surrogate Marker)
2.	Leukocyte L1 Antigen Complex (Calgranulin)
3.	C-Reactive Protein
4.	S100 Proteins (S 100 Protein)
5.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
6.	Apolipoproteins E (ApoE)
7.	Methotrexate (Mexate)
8.	Hydrogen Peroxide (Hydroperoxide)
9.	paquinimod
10.	Lactoferrin

Related Therapies and Procedures

1.	Renal Dialysis (Hemodialysis)
2.	Therapeutics
3.	Artificial Respiration (Mechanical Ventilation)
4.	Peritoneal Dialysis
5.	Length of Stay